NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. The company is headquartered in Emeryville, California and currently employs 14 full-time employees. The company went IPO on 2007-10-26. The firm manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Follow-Up Questions
Qui est le CEO de NovaBay Pharmaceuticals Inc ?
Mr. Justin Hall est le Chief Executive Officer de NovaBay Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action NBY ?
Le prix actuel de NBY est de $1.88, il a increased de 3.8% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de NovaBay Pharmaceuticals Inc ?
NovaBay Pharmaceuticals Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de NovaBay Pharmaceuticals Inc ?
La capitalisation boursière actuelle de NovaBay Pharmaceuticals Inc est de $10.9M
Est-ce que NovaBay Pharmaceuticals Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 2 analystes ont établi des notations d'analystes pour NovaBay Pharmaceuticals Inc, y compris 1 achat fort, 3 achat, 1 maintien, 0 vente et 1 vente forte
